Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib on the Pharmacokinetics of Oral Dextromethorphan in Healthy Participants
NCT07241065Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of capivasertib in breast cancer, sponsored by AstraZeneca. Primary endpoints: Area under concentration time curve from time 0 to infinity of dextromethorphan, Area under concentration curve from time 0 to the last quantifiable concentration of dextromethorphan and 1 more. Started Mar 2026; status: completed.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07241065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241065.